Table 5.
Multivariate regression analysis of factors associated with HCV infection.
| OR | 95% CI | Adjusted p-value | |
|---|---|---|---|
| Anti-HCV seropositivity among all subjects | |||
| Age | 0.98 | 0.92–1.04 | 0.543 |
| AST | 1.03 | 0.94–1.12 | 0.520 |
| ALT | 1.00 | 0.96–1.05 | 0.996 |
| FIB-4 | 1.02 | 0.45–2.33 | 0.955 |
| IDU (yes vs no) | 18.45 | 1.41–241.76 | 0.026 |
| Anti-HBc (positive vs negative) | 0.00 | 0.00- | 1.000 |
| HBV DNA (positive vs negative) | 0.31 | 0.11–0.86 | 0.024 |
| Anti-HDV (positive vs negative) | 12.25 | 4.85–30.93 | 1.1 × 10–7 |
| HCV viremia among anti-HCV (+) subjects | |||
| AST | 1.03 | 0.97–1.09 | 0.363 |
| ALT | 1.05 | 1.02–1.08 | 0.002 |
| BMI | 0.89 | 0.83–0.97 | 0.004 |
| FIB-4 | 0.66 | 0.43–1.01 | 0.056 |
| HBsAg (positive vs negative) | 0.42 | 0.21–0.85 | 0.016 |
| HCV viremia among treatment naïve anti-HCV (+) subjects | |||
| AST | 1.02 | 0.95–1.10 | 0.605 |
| ALT | 1.04 | 1.00–1.08 | 0.060 |
| BMI | 0.86 | 0.79–0.94 | 0.001 |
| FIB-4 | 0.84 | 0.44–1.60 | 0.589 |
| HBsAg (positive vs negative) | 0.27 | 0.13–0.58 | 6.9 × 10–4 |
HCV hepatitis C virus; anti-HCV hepatitis C antibody; AST aspartate aminotransferase; ALT alanine aminotransferase; BMI body mass index; FIB-4 Fibrosis-4 index; IDU injecting drug users; HBsAg hepatitis B surface antigen; anti-HBc hepatitis B core antibody; HBV DNA hepatitis B virus deoxyribonucleic acid; anti-HDV hepatitis D antibody.